Skip to main content

Overview

Dr. Gan studies the molecular mechanisms behind the loss of functional neurons in neurodegenerative diseases, including Alzheimer’s disease and Frontotemporal Dementia. Her lab explores the relationship between the aging of neural circuits, the accumulation of toxic proteins and the subsequent activation of a chronic inflammatory response. Understanding how these processes become dysfunctional in neurodegeneration could lead to new therapeutic strategies to tackle Alzheimer’s disease and Frontotemporal dementia.

Highlights

  1. 1
    Cell · 2022
    PMID: 35063084PMCID: PMC8857049DOISenior author286 citations
  2. 2
    Nature neuroscience · 2023
    PMID: 37095396PMCID: PMC10166855DOISenior author255 citations
  3. 3
    Cell · 2024
    YWYuansong WanAEAlessandro EvangelistiLFLi FanMSManu Sharma+3 more →LGLi Gan
    PMID: 38582079PMCID: PMC11365117DOISenior author65 citations

Publications

154 publications

Active

33 grants
  • Sub-PI
    Mechanisms and intervention of cGAS signaling in brain trauma-induced neuroinflammation and neurodegeneration
    National Institute of Neurological Disorders and Stroke · 2025–2030 · via University of Maryland, Baltimore
  • MPI
    CH25H mediates microglial neuroinflammation and tau toxicities in AD
    National Institute on Aging · 2025–2030
  • PI
    Mapping proteomic changes of tauopathy in human neurons
    National Institute on Aging · 2025–2030
  • KP
    Investigating the role of progranulin microglial replacement therapy in Parkinson's Disease
    National Institute of Neurological Disorders and Stroke · 2026–2028Career
  • Sub-PI
    The Alzheimer's Disease Tau Platform Clinical Trial
    National Institute on Aging · 2023–2028 · via University of California, San Francisco
  • KP
    Investigating Modifiers of Human Microglia-Neuron Interplay in Tau Propagation In Vivo
    National Institute on Aging · 2026–2028Career
  • PI
    Validating STING as a therapeutic target for Parkinson disease using human iPSC models (MJFF-028881) to 2026 RFA: T2T Neuroinflammation Target Validation
    Michael J. Fox Foundation for Parkinson's Research · 2026–2028
    MJFF-028881
  • PI
    Human CGAS inhibitors to treat neurodegeneration in Alzheimer's disease
    NIA · 2026–2028 · via NIH RePORTER
  • Sub-PI
    Study of Selective Cell and System Vulnerability in Alzheimer's Disease
    National Institute on Aging · 2023–2028 · via University of North Carolina at Chapel Hill
  • PI
    Microglial-astrocytic mechanisms of APOE3 Christchurch-mediated resilience to tauopathy
    Cure Alzheimer’s Fund · 2025–2027
    CAF 255893-01
  • PI
    Targeting maladaptive innate immune response to treat PD
    JPB Foundation, The · 2024–2027
    JBP 2024-4710
  • PI
    Systematic Identification of Biomarkers to Distinguish FTD-Tau from TDP-43
    Rainwater Charitable Foundation · 2026–2027
    RCF 261005-01
  • Sub-PI
    Studying NeuroHIV and addictive substances in a human microglia-neuron chimera mouse model
    National Institute on Drug Abuse · 2025–2027 · via The J. David Gladstone Institutes
  • Sub-PI
    Elucidate the Roles of Alzheimer's Disease Variants in Gene Expression and AD Phenotypes
    National Institute on Aging · 2022–2027 · via The Regents of the University of California, San Francisco
  • Co-I
    A calvarial stem cell mediating a new bone-brain axis in Alzheimer's disease
    National Institute on Aging · 2025–2027Career
  • PI
    RCA with Arvinas, Inc
    Arvinas, Inc. · 2026–2027BioPharma Alliance
    BP 262896-01
  • MPI
    cGAS inhibitors for Alzheimer's disease treatment
    National Institute on Aging · 2021–2027
  • Sub-PI
    Hevolution Network on Senescense in Aging
    Hevolution Foundation · 2024–2027 · via Yeshiva University
    AECM 232620-03
  • Co-I
    TREM2 Genotype-Informed Drug Repurposing and Combination Therapy Design for Alzheimer's Disease
    National Institute on Aging · 2022–2027 · via Cleveland Clinic Lerner College of Medicine
  • Sub-PI
    Genome-wide identification and characterization of Alzheimer's Disease-associated enhancers
    National Institute on Aging · 2022–2027 · via Cornell University - Ithaca
  • Sub-PI
    Development of novel genomic approaches for profiling cellular temporal-spatial dynamics of neurogenesis in Aging and Alzheimer's disease
    National Institute on Aging · 2022–2027 · via Rockefeller University
  • PI
    Sex-biased TLR7 signaling in demyelination and its inhibition by small molecules
    Cure Alzheimer’s Fund · 2025–2026
    CAF 245217-01
  • PI
    Genome-scale perturb-seq of human neurons and astrocytes in vivo
    Chan Zuckerberg Initiative · 2025–2026
    CZI 253116-01
  • KP
    Modeling pathological Tau propagation in human brain cells in vivo
    BrightFocus Foundation · 2024–2026
    A2024003F
  • PI
    Methods to optimize the human cGAS inhibitor leads
    Rainwater Charitable Foundation · 2025–2026
    RCF 250950-01
  • PI
    Decoding the molecular mechanisms underlying the copathologies in PSP
    Rainwater Charitable Foundation · 2025–2026
    RCF 251050-01
  • Sub-PI
    Acetylated Tau Immunotherapy for Alzheimer's Disease
    National Institute on Aging · 2024–2026 · via Aeton Therapeutics Inc.
  • PI
    Evaluation of a novel human cGAS inhibitor using human iPSC derived models
    Harrington Discovery Institute, The · 2024–2026
    HDIT 235842-01
  • Co-I
    Structure and Function of Tau
    National Institute on Aging · 2020–2026
  • PI
    Dissecting immune resilience mechanism in human neuron-microglia chimera model
    Carol and Gene Ludwig Family Foundation · 2024–2026
    No publications yet
    CGLFF 242405-02
  • PI
    Biopharma Agreement with NeuroVanda Therapeutics
    Neurovanda Therapeutics Pte. LTD · 2025–2026BioPharma Alliance
    BP 255354-01
  • Co-I
    Elucidating the Cell-Type Specific Neuroprotective Mechanisms in the APOE3 Christchurch Mutation in Alzheimer's Disease
    National Institute on Aging · 2023–2026Fellowship
  • PI
    Maladaptive Antiviral Pathways In Alzheimer'S Disease
    National Institute on Aging · 2021–2026
Completed grants (36)
  • Sub-PI
    CZI DAF
    Chan Zuckerberg Initiative · 2024–2025 · via Silicon Valley Community Foundation
    SVCF 245449-01
  • PI
    Methods to optimize the benzofuran and benzothiophene human cGAS inhibitor leads
    Rainwater Charitable Foundation · 2024–2025
    RCF 241018-01
  • PI
    Model human neuron-microglia interactions in chimera model of PSP and other 4R tauopathies
    Rainwater Charitable Foundation · 2024–2025
    RCF 241019-01
  • KP
    Investigating the role of cGAS signaling and microglial senscence in tauopathy
    National Institute on Aging · 2023–2025
  • KP
    Essential roles of DAP12 in tau metabolism and inflammation in Alzheimer's disease
    National Institute on Aging · 2020–2025
  • Sub-PI
    Optimize virtual hits of human CGAS inhibitor to treat neurodegeneration
    National Institute on Aging · 2023–2025 · via Aeton Therapeutics Inc.
  • PI
    Targeting maladaptive innate immune response to treat PD
    JPB Foundation, The · 2021–2024
    JPB 2021-2957
  • PI
    Rainwater Drug Discovery Grant
    Rainwater Charitable Foundation · 2023–2024
    RCF 230888-01
  • PI
    Model and identify genetic modifiers of PSP 4R tauopathies in human neurons
    Rainwater Charitable Foundation · 2023–2024
    RCF 230889-01
  • KP
    Trem2-APOE Pathway in Alzheimer's Disease: Exploring the differential effects of R47H on the APOE3 and APOE4 backgrounds in a tauopathy model
    National Institute on Aging · 2022–2024
  • Sub-PI
    Exploring HIV-associated Neurocognitive Disorder (HAND) and HIV Latency at the Single Cell Level in Cerebral Organoids
    National Institute on Drug Abuse · 2020–2024 · via The J. David Gladstone Institutes
  • PI
    Human cGAS small molecule inhibitors
    Cure Alzheimer’s Fund · 2021–2024
    CAF 213682-03
  • PI
    Development of cGAS Inhibitors to Treat Neurodegenerative Diseases
    Daedalus Fund for Innovation (Weill Cornell) · 2021–2024BioPharma Alliance
    BP 214753-01
  • Co-I
    The Role of Transposable Elements in Healthy Aging and in Alzheimer's Disease
    National Institute on Aging · 2022–2024
  • PI
    Rainwater
    Rainwater Charitable Foundation · 2022–2024
    RCF 223643-01
  • PI
    Sadaf Amin's BrightFocus Fellowship, "The Role of cGAS-STING Signaling in Neuroinflammation and Alzheimer's Disease"
    BrightFocus Foundation · 2020–2023
    BFF 211109-02
  • PI
    Rainwater
    Rainwater Charitable Foundation · 2022–2023
    RCF 228257-01
  • PI
    Addgene 703132
    Addgene, Inc. · 2022–2023
    Addgene 703132
  • PI
    Addgene 698729
    Addgene, Inc. · 2022–2023
    Addgene 698729
  • PI
    Addgene 697783
    Addgene, Inc. · 2022–2023
    Addgene 697783
  • PI
    Addgene 696309
    Addgene, Inc. · 2022–2023
    Addgene 696309
  • Sub-PI
    Study of Selective Cell and System Vulnerability in Alzheimer's Disease
    National Institute on Aging · 2022–2023 · via University of North Carolina at Chapel Hill
  • PI
    Tau acetylation in Alzheimer's disease
    National Institute on Aging · 2019–2023
  • PI
    Linking tau proteostasis with neuronal activity in FTD
    National Institute of Neurological Disorders and Stroke · 2018–2023
  • PI
    Development of best-of-class Inhibitors of cGAS to treat tauopathy
    Rainwater Charitable Foundation · 2021–2022
    RCF 221502-01
  • Sub-PI
    Functional Characterization of Alzheimer's Disease Associated Genetic Variants
    National Institute on Aging · 2019–2022 · via University of California, San Francisco
  • PI
    Targeting maladaptive innate immune response to treat PD
    JPB Foundation, The · 2019–2021
    JPB 194610-02
  • KP
    Elucidating The Microglial Mechanisms Underlying Sex-Specific Neuroinflammation In Alzheimer'S Disease.
    National Institute on Aging · 2021–2021Fellowship
  • PI
    Targeting microglial-mediated toxicity to treat tauopathies
    Rainwater Charitable Foundation · 2020–2021
    RCF 203805-01
  • PI
    Project 1: Targeting microglial-mediated toxicity treat tauopathy
    Rainwater Charitable Foundation · 2019–2020
    RCF 193898-01
  • PI
    Molecular mechanisms in progranulin deficient frontotemporal dementia
    National Institute on Aging · 2019–2020
  • PI
    Tau Consortium
    Rainwater Charitable Foundation · 2018–2019
    RCF 190078-01
  • PI
    Screening for inhibitors of p300-mediated tau acetylation for Alzheimer's Disease
    NIA · 2014–2017 · via NIH RePORTER
  • PI
    SIRT1 Limits Microglial Toxicity in Alzheimer's Disease
    NIA · 2012–2017 · via NIH RePORTER
  • PI
    The Role of Cathepsin B and Cystatin C in Alzheimer's Disease
    NIA · 2010–2015 · via NIH RePORTER
  • PI
    Cathepsin B and cystatin C in AD-related neuronal damage
    NIA · 2004–2006 · via NIH RePORTER

Available technologies

News mentions

Show 17 more mentions

Media highlights

1 clip
11 PhD students · 13 Postdocs

External relationships

Ownership

Aeton Therapeutics Inc. · LSG Therapeutics, LLC · Neurovanda Therapeutics Pte. LTD · Theseus Therapies INC

Advisory/Scientific Board Member

Arvinas, Inc. · Neurovanda Therapeutics Pte. LTD

Proprietary Interest

Aeton Therapeutics Inc.

Other

Aeton Therapeutics Inc. · LSG Therapeutics, LLC · Theseus Therapies INC